X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ABBOTT INDIA VENUS REMEDIES/
ABBOTT INDIA
 
P/E (TTM) x -836.1 42.3 - View Chart
P/BV x 0.2 10.6 2.3% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   ABBOTT INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ABBOTT INDIA
Mar-16
VENUS REMEDIES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs2186,015 3.6%   
Low Rs823,707 2.2%   
Sales per share (Unadj.) Rs365.61,236.9 29.6%  
Earnings per share (Unadj.) Rs1.5122.2 1.2%  
Cash flow per share (Unadj.) Rs37.9129.0 29.4%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs382.5521.2 73.4%  
Shares outstanding (eoy) m11.4421.25 53.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.9 10.4%   
Avg P/E ratio x101.039.8 253.8%  
P/CF ratio (eoy) x4.037.7 10.5%  
Price / Book Value ratio x0.49.3 4.2%  
Dividend payout %028.6 0.0%   
Avg Mkt Cap Rs m1,717103,296 1.7%   
No. of employees `0001.03.0 34.5%   
Total wages/salary Rs m3243,370 9.6%   
Avg. sales/employee Rs Th4,100.78,891.8 46.1%   
Avg. wages/employee Rs Th318.01,140.0 27.9%   
Avg. net profit/employee Rs Th16.7878.3 1.9%   
INCOME DATA
Net Sales Rs m4,18326,284 15.9%  
Other income Rs m20504 4.0%   
Total revenues Rs m4,20326,789 15.7%   
Gross profit Rs m8123,665 22.1%  
Depreciation Rs m417144 288.6%   
Interest Rs m3808 4,688.9%   
Profit before tax Rs m354,017 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m181,421 1.3%   
Profit after tax Rs m172,596 0.7%  
Gross profit margin %19.413.9 139.1%  
Effective tax rate %51.635.4 145.8%   
Net profit margin %0.49.9 4.1%  
BALANCE SHEET DATA
Current assets Rs m2,77114,446 19.2%   
Current liabilities Rs m1,9314,725 40.9%   
Net working cap to sales %20.137.0 54.3%  
Current ratio x1.43.1 46.9%  
Inventory Days Days12551 243.3%  
Debtors Days Days5420 274.8%  
Net fixed assets Rs m5,3281,113 478.8%   
Share capital Rs m114213 53.8%   
"Free" reserves Rs m4,17710,808 38.6%   
Net worth Rs m4,37611,076 39.5%   
Long term debt Rs m1,9110-   
Total assets Rs m8,42816,241 51.9%  
Interest coverage x1.1497.0 0.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.6 30.7%   
Return on assets %4.716.0 29.4%  
Return on equity %0.423.4 1.7%  
Return on capital %6.636.3 18.2%  
Exports to sales %00.6 0.0%   
Imports to sales %20.512.6 162.3%   
Exports (fob) Rs mNA162 0.0%   
Imports (cif) Rs m8583,322 25.8%   
Fx inflow Rs m0268 0.0%   
Fx outflow Rs m8583,927 21.9%   
Net fx Rs m-858-3,659 23.5%   
CASH FLOW
From Operations Rs m4692,514 18.6%  
From Investments Rs m29-800 -3.7%  
From Financial Activity Rs m-464-803 57.7%  
Net Cashflow Rs m35912 3.8%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 7.9 2.3%  
FIIs % 0.6 0.1 580.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.1 388.3%  
Shareholders   20,121 18,270 110.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  WYETH LTD  GSK PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 22, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - DR. DATSONS LABS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS